Michael I. Dorrell Ph.D.

Professor of Biology: Point Loma Nazarene University 3900 Lomaland Drive, San Diego CA 92106; email: mdorrell@pointloma.edu

3900 Lomaiand Drive, San Diego CA 92106; email: mdorreil@pointioma.edu				
Professional Preparation				
Institution	(T.A.)	Major (2.00	Degree	Year 1000
Simpson College (IA)		Chemistry / Math (3.98gpa)	B.A.	1998
The Scripps Research Institute		Biomedical Research	Ph.D.	2003
The Scripps Re	search Institute	Cell and Developmental Bio	Post-doc	2004-2009
Appointments				
11/15 – present	t Full professor of	f Biology: Point Loma Nazaro	ene University	
	- Teaching vario	us biology courses at all levels	including GE,	freshman majors,
	upper division	requirements and electives, and	graduate cours	es.
	- Research study	ring targeted methods of treati	ng glioblaston	na brain cancers.
	Focuses on ant	i-angiogenic treatments and AD	EP therapy.	
09/14 – present	t Staff consultant	: Lowy Medical Research Ins	titute	
	_	g studies investigating eye dis-		_
		duced pluripotent stem cells, and		2
		ral and extramural studies of fur		d the world
08/12 - 11/15	-	sor: Point Loma Nazarene U	•	
08/09 – 08/12 Assistant professor: Point Loma Nazarene University				
06/13 - 08/14		ntist: Lowy Medical Research		
		from PLNU (two summers and	_	• /
		ew institute dedicated to the stu		
		sted hypotheses of the causes of	of MacTel base	d on clinical and
	basic research			
0.0.40.0		acTel-based clinical and basic r		the globe.
08/09 – present Adjunct professor: The Scripps Research Institute				
2010 – 2012		tant: EyeCyte Inc.		
2007- 2009		or: University of San Diego.	•.1	. 1 1
0.4/05.00/00		e per semester in conjunction w	• •	
04/05-08/09		low (Research Associate), The		
		pased therapies for the treatment		
05/04/04/05		pination angiostatic therapies for		astoma cancers.
05/04-04/05	Research Scienti	st, Angiosyn Inc. San Diego, C	A 1- (T2 TD	(C) -14i1
		he use of an angiostatic molecular forms in the alimin (or		
00/02 05/04		ate work, for use in the clinic (p		b by Pfizer)
09/03-05/04		Itant, Angiosyn Inc. San Diego		$C\Lambda$
05/03-05/04		ate, The Scripps Research Ins		
		factor during developmental reti	~ ~	
1009 05/02	•	ification, biochemical purification, The Scripps Research Insti		
1998-05/03		uidance and Vascular Patterning du		
2000-2001		iltant, Nanogen Inc. San Diego	-	Сюринен
2000-2001		n tools and analyses, helped imp		aPCR program
	Gene expression	in tools and analyses, neiped imp	picinicin a new	qi Cik piogiani

Teaching Experience

Point Loma Nazarene University

- University Now; Outreach program to under-priveleged high school students where we teach the students Bio101 (General elective human biology) and writing.
- Human Biology and Bioethics (Bio101), General education elective
- Cell Biology and Biochemistry (Bio210), Introductory level course for Biology majors
- Research Methodology (Bio301), Biology major's quad course. I specifically designed this course to teach students how to think like a scientist. The core project of the course is for the students to research the literature and create a novel grant proposal in biology.
- Advanced Cell Biology (Bio350), Biology major's course. I completely re-designed this course to reflect active learning in the manner of a "flipped course" whereby the students learn and teach each other content prior to coming to class to grapple with higher level concepts and projects.
- Developmental Biology (Bio400), Biology major's upper division elective. I added a half-semester laboratory project whereby students design and implement their own experiments studying teratogens and their effects on zebrafish development.
- Senior Seminar (Bio497), Senior capstone course in biology.
- Graduate-level Cell Biology (Bio663), 3-week intensive summer course for biology master's students to teach in-depth topics in cell function.
- Graduate-level Developmental biology (Bio664), 3-week intensive summer course for biology master's students: principles of development, cell differentiation, and evolution.
- Perspectives on Science (Bio695), Graduate level journal club style course.

University of San Diego

- Topics in human biology (Bio104), General biology course for non-majors
- Introduction to Cell Processes (Bio225), Cell and molecular biology course for biology and chemistry majors
- Genetics (Bio300), Genetics course for biology majors
- Genetics lab (Bio300L), Separate lab course designed to teach genetics lab methods
- Senior seminar (Bio495), Analysis and presentation of primary literature for senior biology majors

The Scripps Research Institute

- Undergraduate research supervisor
- Director of the Scripps Outreach Programs; organized curriculum for a 10 week course preparing high school students for summer internships in biomedical research, and an 8 week program presenting high school teachers with current theories and experimental methods in biomedical research
- Teacher in the Scripps Outreach Program; various courses including immunology, virology, cell and molecular biology, structural biology, and bioinformatics.

<u>Bowdoin College (1 semester)</u>; Assisted professors through direct lecture and lab presentations

• Virology (Bio303), Human Genetics (Bio255), Topics in Neuroscience (Bio325), Introduction to Biology (Bio104), Cell Biology (Bio224), Biochemistry lab (Bio263)

Synergistic Activities

1999 - present Undergraduate research mentor (TSRI and PLNU):

- Mentored multiple undergraduate students in the design and implementation of independent research projects. Several undergraduates became co-authors on publications.

2000 - present Member: Association for Research in Vision and Ophthalmology

- Yearly attendance and invited oral research presentations ('02, '03, '04, '05, '07, '08, '09, '14) at the annual meeting for vision research (ARVO).

Spring 1999 - 2003 Director / Teacher: Scripps Outreach Programs:

- Annually organized curriculum and taught a 10 week course preparing high school students for summer internships in biomedical research at The Scripps Research Institute.
- Annually organized and taught an 8 week course at TSRI presenting high school teachers with current theories and experimental methods in biomedical research.

2004 – present Ad hoc reviewer (Nature Medicine, IOVS, Retina, Exp. Eye Research, PLoS One, Journal of Clinical Investigation)

Honors and Awards

2016	Alumni grant award; Point Loma Nazarene University
2010, 2012, 2014, 2016	RASP grant; Point Loma Nazarene University
2006 - 2009	California Institute of Regenerative Medicine (CIRM) fellowship
2000-20003	Achievement Recognition for Collegiate Scientists (ARCS) fellowship
2003	Travel Grant – Association for Research in Vision and Ophthalmology
2002	Travel Grant - International Society of Differentiation
1998	Awards for Top Student in Chemistry and Mathematics, Simpson

Selected Volunteer Work

Tierresanta Lutheran Church: Youth Sunday school teacher; 2011 – present.

Tierresanta Lutheran Church: Vacation bible school coordinator and volunteer; 2010 – present.

St. Marks United Methodist Church: Youth fellowship leader 1998 - 2007.

St. Marks United Methodist Church: Pastoral and church relations committee 2000 - 2004 Youth soccer coach: Coached youth soccer at the YMCA and in AYSO 2007 - 2012

'Kickin-it' annual charity soccer event: Co-organizer and volunteer 2005-2009; (local charity event envisioned, organized, and implemented by my co-ed soccer team to help local families in need).

<u>Publications:</u> (* indicates undergraduate interns under my mentorship included as co-authors)

- 1) Usui Y, Westenskow PD, Murinello S, **Dorrell MI**, Scheppke L, Bucher F, Sakimoto S, Paris LP, Aguilar E, Friedlander M. (2015) <u>Angiogenesis and Eye Disease</u>. *Annu Rev Vis Sci*. Nov; 24;1:155-184.
- *2) Usui Y, Westenskow PD, Kurihara T, Aguilar E, Sakimoto S, Paris LP, Wittgrove C, Feitelberg D, Friedlander MS, Moreno SK, **Dorrell MI (co-corresponding author)**, Friedlander M. (2015) Neurovascular crosstalk between interneurons and capillaries is required for vision. *J Clin Invest*. Jun; 125(6):2335-46
- *3) **Michael I. Dorrell**, Michael Marcacci, Stephen Bravo, Troy Kurz, Jacob Tremblay, Jack C. Rusing. (2012) Ex Ovo Model for Directly Visualizing Chick Embryo Development. *American Biology Teacher (ABT)*. Nov/Dec 2012;74(9): 628 634.
- *4) Weidemann A, Krohne TU, Aguilar E, Kurihara T, Takeda N, **Dorrell MI**, Simon MC, Haase VH, Friedlander M, Johnson RS. (2010) <u>Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina</u>. *Glia* Aug;58(10):1177-85
- *5) **Michael I. Dorrell,** Edith Aguilar, Ruth Jacobson, Sunia A. Trauger, Jeffrey Friedlander, Gary Siuzdak, Martin Friedlander. (2010) <u>Rescuing astrocytes normalizes revascularization and prevents vascular pathology associated with oxygen induced retinopathy. *Glia* Jan 1;58(1):43-54.</u>
- 6) **Michael I. Dorrell,** Edith Aguilar, Ruth Jacobson, Ray Gariano, John Heckenlively, Eyal Banin, G. Anthony Ramirez, Mehdi Gasmi, Alan Bird, Martin Friedlander. (2009) <u>Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. *J Clin Invest.* March;119(3):611-623.</u>
- 7) **Michael I. Dorrell,** Edith Aguilar, Lea Scheppke, Faith Barnett, Martin Friedlander. (2007) <u>Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis.</u> *Proc. Natl. Acad. Sci.* Jan 16;104(3): 967-972.
- 8) Matthew R. Ritter, Eyal Banin, Stacey K. Moreno, Edith Aguilar, **Michael I. Dorrell**, and Martin Friedlander. (2006) <u>Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy</u>. *J Clin Invest*. Dec;116(12):3266-76.
- *9) **Michael I. Dorrell**¹, Eyal Banin ¹, Edith Aguilar, Chris M. Aderman, Alex C. Smith, Jeffrey Friedlander, Martin Friedlander (2006) <u>T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification</u>. *Invest Ophthalmol Vis Sci.* May;47(5): 2125-2134.
- 10) Atsushi Otani, **Michael I. Dorrell**, Karen Kinder, Stacey K. Moreno, Steven Nusinowitz, Eyal Banin, John Heckenlively, and Martin Friedlander. (2004) <u>Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lin- hematopoietic stem cells</u>. *J Clin Invest* Sept;114(6):765-774.

- 11) **Michael I. Dorrell¹,** Mattias Belting¹, Staffan Sandgren, Edith Aguilar, Jasimuddin Ahamed, Andrea Dorfleutner, Peter Carmeliet, Barbara M. Mueller, Martin Friedlander, and Wolfram Ruf. (2004) Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. *Nat Med.* May;10(5):502-509.
- 12) **Michael I. Dorrell,** Atsushi Otani, Edith Aguilar, Stacey K. Moreno, and Martin Friedlander. (2004) <u>Targeting of bone-marrow derived hematopoietic stem cells to the developing retinal vasculature is mediated by R-cadherin</u>. *Blood*. May 1;103(9): 3420-3427.
- *13) **Michael I. Dorrell,** Edith Aguilar, Christoph Weber, and Martin Friedlander. (2004) <u>Global analysis of gene expression during mouse retina development.</u> *Invest Opthalmol Vis Sci.* Mar;45(3):1009-19.
- *14) Matthew R. Ritter, Stacey K. Moreno, **Michael I. Dorrell**, *et al.* (2003) <u>Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis A possible role for the immune system during involution</u>. *Lymphatic Res. Biol.* April;1(4):291-300.
- 15) **Michael I. Dorrell**, Edith Aguilar, and Martin Friedlander (2002) <u>Retinal vascular development is mediated by endothelial filopodia</u>, a pre-existing astrocytic template, and Specific R-cadherin adhesion. *Invest Opthalmol Vis Sci.* Nov:43(11):3500-3510.
- 16) Matthew R. Ritter, **Michael I. Dorrell**, Joseph Edmonds, Sheila Friedlander and Martin Friedlander (2002) <u>Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis</u>. *Proc. Natl. Acad. Sci.* May 28;99(11):7455-60.
- 17) Atsushi Otani, Bonnie M. Slike, **Michael I. Dorrell**, John Hood, Karen Kinder, Karla L. Ewalt, David Cheresh, Paul Schimmel, and Martin Friedlander (2002) <u>A fragment of human TrpRS as a potent antagonist of ocular angiogenesis</u>. *Proc. Natl. Acad. Sci.* Jan 8;99(1):178-83.
- 18) Hans E. Purkey, **Michael I. Dorrell**, and Jeffrey Kelly (2001) <u>Evaluating the binding selectivity of transthyretin amyloid inhibitors in blood plasma</u>. *Proc. Natl. Acad. Sci.* May 8;98(10):5566-71.

Invited Reviews

- Edith Aguilar, **Michael I. Dorrell**, David Friedlander, et al. (2008) <u>Ocular Models of Angiogenesis</u>. *Methods Enzymol*. 444:115-58.
- Martin Friedlander, **Michael I. Dorrell**, Matthew R. Ritter, et al. (2007) <u>Progenitor cells and retinal angiogenesis</u>. *Angiogenesis*. March; 10(2):89-101.
- **Michael I. Dorrell,** Hannele Uusitalo, Edith Aguilar, Martin Friedlander. (2007) <u>Ocular angiogenesis</u>; basic mechanisms and therapeutic advances. *Survey of Ophthalmology*. Jan; 52(sup. 1): S3-S19.
- **Michael I. Dorrell,** Martin Friedlander. (2006) <u>Mechanisms of endothelial cell guidance during retinal vascular development</u>. *Progress in Retinal and Eye Research*. May;25(3):277-95.

Book Chapters

- Yoshihiko Usui, Peter D. Westenskow, Salome Murinello, **Michael I. Dorrell**, Leah Scheppke, Felicitas Bucher, Susumu Sakimoto, Liliana P. Paris, Edith Aguilar, and Martin Friedlander. <u>Angiogenesis and Eye Disease</u>. *Annual Review of Vision Science*. Volume 1, 2015. J.A. Movshon and B.A. Wandall (co-editors). Annual Reviews, Palo Alto, CA. USA. 2015. Pages 155 184.
- **Michael I. Dorrell** and Martin Friedlander. <u>Retinal vascular and retinal pigment epithelium gene expression.</u> *Eye, Retina, and Visual System of the Mouse.* L.M. Chalupa and R.W. Williams (Eds). MIT Press. USA. 2008. Pages 685-696.
- Michael I. Dorrell, Martin Friedlander, Lois E. H. Smith. <u>Retinal vascular development</u>. *Retinal Vascular Disease*. A.M. Joussen, T.W. Gardner, B. Kirchhof, and S.J. Ryan (Eds). Springer. Germany, 2007. Pages 24-35.

Patents:

- U.S. Provisional Patent, Serial No. 60/562,821, "Methods of Modulating Vascularization"
- U.S. Provisional Patent, Serial No. 60/577,156, "Compositions and Methods for Treatment of Neovascular Diseases"
- U.S. Provisional Patent, Serial No. 10/836,289. "Selective R-Cadherin Antagonists and Methods"